AntiCancerCancer’s PDOX Mouse Model Has Demonstrated High Clinical Concordance Which Will Enable Precise Individualized Chemotherapy of Cancer Patients
02 Oct 2023
SAN DIEGO--(BUSINESS WIRE)-- AntiCancer Inc.Cancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient. “This new result means AntiCancerCancer has made the first steps for precise, individualized cancer chemotherapy,” said Qinghong Han, Senior Scientist at AntiCancer Inc.Cancer Inc. “The PDOX mouse model has the patient’s tumor implanted in the same organ in the mouse as it was in the patient enabling very accurate prediction of chemotherapy outcome for the patient,” said Dr. Han.
“AntiCancerCancer’s technique of patient-tumor establishment in mice is close to 100%, making the PDOX model available potentially to all patients,” technique-inventor and AntiCancerCancer-Japan General Manager Chihiro Hozumi said.
AntiCancerCancer has published 165 scientific papers on its PDOX model since 1991. The latest paper on clinical concordance of the PDOX model is published in the October 2023 issue of Anticancer Research.
AntiCancer Inc.Cancer Inc., San Diego, is a world leader in mouse models of cancer; small-animal imaging; methionine-restriction treatment of cancer; bacterial therapy of cancer, adult stem cells for regenerative medicine, in vitro assays of cancer therapy, a pioneer in fluorescence-guided surgery, and more, demonstrated in 1200 scientific publications and almost 200 patents. AntiCancer Inc.Cancer Inc. was founded in 1984.
View source version on businesswire.com:
Contacts
Qinghong Han, MD
all@anticancer.com
Source: AntiCancer Inc.Cancer Inc.
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.